Apellis Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
31/07/2025 14:31
Apellis Pharmaceuticals Inc APLS.OQ reported a quarterly adjusted loss of 33 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -28 cents. The mean expectation of twenty one analysts for the quarter was for a loss of 48 cents per share. Wall Street expected results to range from -75 cents to -27 cents per share. Revenue fell 10.6% to $178.49 million from a year ago; analysts expected $188.52 million. Apellis Pharmaceuticals Inc's reported EPS for the quarter was a loss of 33 cents. The company reported a quarterly loss of $42.15 million. Apellis Pharmaceuticals Inc shares had risen by 9.8% this quarter and lost 40.5% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 80.9% in the last three months. In the last 30 days, two analysts negatively revised earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Apellis Pharmaceuticals Inc is $29.00, about 34.5% above its last closing price of $19.00 This summary was machine generated from LSEG data July 31 at 01:30 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.48 | -0.33 | Beat |
| Mar. 31 2025 | -0.36 | -0.74 | Missed |
| Dec. 31 2024 | -0.39 | -0.29 | Beat |
| Sep. 30 2024 | -0.30 | -0.46 | Missed |